Mini ReviewOpen Access

Pros and Cons of Monoclonal Antibodies Fixed Dosing Administration in Cancer Patients

Volume 4 - Issue 2

**Alfredo Tartarone*, Rosa Lerose and Michele Aieta**

Author Information Open or Close
- Department of Onco-Hematology, IRCCS-CROB Referral Cancer Center of Basilicata, Italy
*Corresponding author:Alfredo Tartarone, Department of Onco-Hematology, Unit of Medical Oncology, IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture (Pz), Italy

Received: April 15, 2018; Published: April 30, 2018

DOI: 10.26717/BJSTR.2018.04.001015

Full Text PDF

To view the Full Article Peer-reviewed Article PDF

Abstract

Monoclonal antibodies (mAbs) in oncology are usually administered in body-size-based or fixed dosing schedules. However, the minor effects of body size on distribution and elimination of mAbs, as well as a series of practical advantages could support their fixed dosing use.

Kewords: FDA: US Food and Drug Administration; EMA: European Medicines Agency; NSCLC: Non Small Cell Lung Cancer; RCC: Renal Cell Carcinoma; BC: Breast Cancer; UC: Urothelial Carcinoma; CHL: Classical Hodgkin’s Lymphoma; HNSCC: Head and Neck Squamous Cell Carcinoma; HCC: Hepatocellular Carcinoma; GC: Gastric Cancer; CLL: Cronic Lymphocytic Leukaemia; NHL: Non-Hodgkin’s Lymphoma; FL: Follicular Lymphoma; DLBCL: Diffuse Large B-Cell Lymphoma; ; MSI-H: High Microsatellite Instability; IV: Intravenous; SC: SubCutaneous Q2W: Every Two Weeks; Q4W: Every Four Weeks

Abstract| References|